iBio Announces New Investments from Board Members and Officers

Core Insights - iBio, Inc. has successfully closed a private placement offering totaling over $650,000 with its Board of Directors and Officers, indicating strong internal support for the company's strategic direction [1][2] Company Overview - iBio is an AI-driven biotech company focused on developing precision antibody immunotherapies for cardiometabolic diseases, obesity, cancer, and other challenging diseases [4] - The company utilizes advanced computational biology and proprietary 3D modeling to create a pipeline of innovative therapeutics aimed at addressing significant unmet medical needs [4] Product Pipeline - iBio is developing a pipeline of therapeutics specifically targeting cardiometabolic diseases and obesity, with a focus on promoting healthy weight loss [3] - The antibody treatments are designed to reduce obesity while preserving muscle mass, promoting muscle growth, and preventing weight regain [3] - The company's machine-learning-based drug discovery platform is aimed at creating candidates with high developability and an extended half-life, potentially allowing for reduced dosing compared to current obesity therapeutics [3]